Clover Biopharmaceuticals Management
Management criteria checks 1/4
Clover Biopharmaceuticals' CEO is Joshua G. Liang, appointed in Dec 2020, has a tenure of 3.33 years. total yearly compensation is CN¥30.29M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 1.58% of the company’s shares, worth HK$6.76M. The average tenure of the management team and the board of directors is 2.3 years and 2.6 years respectively.
Key information
Joshua G. Liang
Chief executive officer
CN¥30.3m
Total compensation
| CEO salary percentage | 26.9% |
| CEO tenure | 3.3yrs |
| CEO ownership | 1.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥139m |
| Sep 30 2023 | n/a | n/a | -CN¥402m |
| Jun 30 2023 | n/a | n/a | -CN¥665m |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥30m | CN¥8m | -CN¥2b |
| Sep 30 2022 | n/a | n/a | -CN¥4b |
| Jun 30 2022 | n/a | n/a | -CN¥6b |
| Mar 31 2022 | n/a | n/a | -CN¥6b |
| Dec 31 2021 | CN¥15m | CN¥8m | -CN¥6b |
| Dec 31 2020 | CN¥4m | CN¥4m | -CN¥913m |
Compensation vs Market: Joshua G.'s total compensation ($USD4.18M) is above average for companies of similar size in the Hong Kong market ($USD232.54K).
Compensation vs Earnings: Joshua G.'s compensation has increased whilst the company is unprofitable.
CEO
Joshua G. Liang (30 yo)
3.3yrs
Tenure
CN¥30,285,000
Compensation
Mr. Joshua G. Liang is Executive Director and Chief Executive Officer at Clover Biopharmaceuticals, Ltd. since December 25, 2020. Mr. Liang is primarily responsible for leading the management and operation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.5yrs | CN¥10.45m | 16.17% CN¥ 69.2m | |
| CEO & Executive Director | 3.3yrs | CN¥30.29m | 1.58% CN¥ 6.8m | |
| Chief Financial Officer | 1.8yrs | no data | no data | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| Chief People Officer | 2.3yrs | no data | no data | |
| Chief Medical Officer of Vaccine | 3.2yrs | no data | no data | |
| Chief Technical Operation Officer | no data | no data | no data | |
| Senior Vice President of Corporate Strategy & Business Development | 2.3yrs | no data | no data | |
| Senior Vice President of Head of Regulatory Affairs | 2.3yrs | no data | no data | |
| President of Global Research & Development | 2.2yrs | no data | no data | |
| President of Greater China | 2yrs | no data | no data | |
| Executive Vice President of Global Clinical Development Vaccines | 1.8yrs | no data | no data |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: 2197's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.5yrs | CN¥10.45m | 16.17% CN¥ 69.2m | |
| CEO & Executive Director | 3.3yrs | CN¥30.29m | 1.58% CN¥ 6.8m | |
| Independent Non-Executive Director | 2.6yrs | CN¥2.21m | 0.023% CN¥ 99.3k | |
| Non-Executive Director | 1.8yrs | CN¥1.30m | 0.053% CN¥ 226.8k | |
| Non-Executive Director | 3.1yrs | CN¥2.20m | 2.18% CN¥ 9.3m | |
| Non-Executive Director | 1.8yrs | CN¥527.00k | 0.012% CN¥ 51.8k | |
| Independent Non-Executive Director | 2.6yrs | CN¥2.32m | 0.023% CN¥ 99.3k | |
| Independent Non-executive Director | 2.6yrs | CN¥2.29m | 0.023% CN¥ 99.3k | |
| Independent Non-Executive Director | 2.6yrs | CN¥2.21m | 0.023% CN¥ 99.3k |
2.6yrs
Average Tenure
61yo
Average Age
Experienced Board: 2197's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.